If you have followed On The Pen for any length of time, you have heard us talk about the cardiovascular benefits of GLP-1 drugs again and again. Wegovy has shown a reduction in major cardiovascular events, the broader GLP-1 class continues to produce cardiovascular signals, and just recently at EASD 2026, Lilly added encouraging heart data for Foundayo,…